We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol (ACTFAST SWISS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00136942
Recruitment Status : Completed
First Posted : August 29, 2005
Last Update Posted : March 3, 2008
Sponsor:
Information provided by:
Pfizer

Brief Summary:
The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Condition or disease Intervention/treatment Phase
Hyperlipidemia Drug: Atorvastatin Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 370 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, 6-Week-Treatment, Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin
Study Start Date : April 2005





Primary Outcome Measures :
  1. The proportion of patients achieving LDL-C target as defined by local swiss AGLArecommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Secondary Outcome Measures :
  1. The proportion of patients across different AGLA-categories (primary and secondary prevention) achieving LDL-C target as defined by AGLA-recommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening
  • LDL-C < 6.0 mmol/l
  • Triglyceride level < 5.0 mmol/l.

Exclusion Criteria:

  • Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy (LLT) at screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00136942


Locations
Switzerland
Pfizer Investigational Site
Langenthal, BE, Switzerland
Pfizer Investigational Site
Thun, BE, Switzerland
Pfizer Investigational Site
Binningen, BL, Switzerland
Pfizer Investigational Site
Liestal, BL, Switzerland
Pfizer Investigational Site
Basel, BS, Switzerland
Pfizer Investigational Site
Duedingen, FR, Switzerland
Pfizer Investigational Site
Geneve, GE, Switzerland
Pfizer Investigational Site
Onex, GE, Switzerland
Pfizer Investigational Site
Pfaeffikon, SZ, Switzerland
Pfizer Investigational Site
Siebnen, SZ, Switzerland
Pfizer Investigational Site
Lugano, TI, Switzerland
Pfizer Investigational Site
Malvaglia, TI, Switzerland
Pfizer Investigational Site
Melide, TI, Switzerland
Pfizer Investigational Site
Vezia, TI, Switzerland
Pfizer Investigational Site
Ecublens, VD, Switzerland
Pfizer Investigational Site
Lausanne, VD, Switzerland
Pfizer Investigational Site
Prilly, VD, Switzerland
Pfizer Investigational Site
Unteraegeri, ZG, Switzerland
Pfizer Investigational Site
Zug, ZG, Switzerland
Pfizer Investigational Site
Zuerich, ZH, Switzerland
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
ClinicalTrials.gov Identifier: NCT00136942     History of Changes
Other Study ID Numbers: A2581089
First Posted: August 29, 2005    Key Record Dates
Last Update Posted: March 3, 2008
Last Verified: April 2007

Additional relevant MeSH terms:
Hyperlipidemias
Hyperlipoproteinemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Atorvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors